|
|
Volumn 7, Issue 11, 2008, Pages 880-881
|
|
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICONVULSIVE AGENT;
CARBAMIC ACID DERIVATIVE;
PHENYLENEDIAMINE DERIVATIVE;
RETIGABINE;
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
DRUG INDUSTRY;
DRUG LEGISLATION;
ECONOMICS;
EPILEPSY;
LEGAL ASPECT;
NOTE;
ANTICONVULSANTS;
CARBAMATES;
CLINICAL TRIALS AS TOPIC;
COMMERCE;
DRUG INDUSTRY;
EPILEPSY;
LEGISLATION, DRUG;
PHENYLENEDIAMINES;
|
|
EID: 56049095490
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2752 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|